
CLAIMS

1.

Use of (a) an amount of a compound of Formula (I):



(I),

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is H, F or Cl;

R^2 is C_1-C_4 alkyl, where said C_1-C_4 alkyl is optionally substituted by R^5;

R^3 is H or C_1-C_4 alkyl, where said C_1-C_4 alkyl is optionally substituted by R^6;

R^4 is H or F; and

each R^5 and R^6 is independently OH, F or C_1-C_2 alkoxy; and

(b) an amount of an antiandrogen in the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered to a subject in need thereof, and

wherein the amounts in (a) and (b) together are effective in treating cancer.

2. The use of claim 1, wherein the compound of Formula (I) is 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1*H*-benz-imidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-*threo*-pentitol, or a pharmaceutically acceptable salt thereof.

3. The use of claim 1 or 2, wherein the antiandrogen is selected from the group consisting of enzalutamide, N-desmethyl enzalutamide, darolutamide, apalutamide, and abiraterone, or a pharmaceutically acceptable salt or solvate thereof.

4. The use of claim 3, wherein the antiandrogen is enzalutamide or a pharmaceutically acceptable salt or solvate thereof.

5. The use of any one of claims 1 to 4, wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, lung cancer, liver cancer, kidney

cancer, bladder cancer, ovarian cancer, peritoneal cancer, fallopian tube cancer, cervical cancer, uterine cancer, pancreatic cancer, stomach cancer, colorectal cancer, esophageal cancer, head and neck cancer, testicular cancer, adrenal cancer, skin cancer, brain cancer, sarcoma, and lymphoma.

6. The use of claim 5, wherein the cancer is prostate cancer.

7. The use of claim 6, wherein the prostate cancer is metastatic prostate cancer (mPC).

8. The use of claim 6, wherein the prostate cancer is non-metastatic prostate cancer (nmPC).

9. The use of any one of claims 6 to 8, wherein the prostate cancer is resistant to enzalutamide or abiraterone.

10. The use of any one of claims 1 to 9, wherein (c) an amount of an additional anti-cancer agent is to be administered to the subject thereof; and wherein the amounts in (a), (b) and (c) together are effective in treating cancer.

11. The use of claim 10, wherein the additional anti-cancer agent is selected from the group consisting of an anti-tumor agent, an anti-angiogenesis agent, a signal transduction inhibitor, an antiproliferative agent, and an androgen deprivation therapy (ADT).

12. The use of claim 11, wherein the additional anti-cancer agent is an ADT.


13. The use of claim 12, wherein the ADT is selected from the group consisting of a gonadotropin releasing hormone (GnRH) agonist and a gonadotropin releasing hormone (GnRH) antagonist.

14. The use of claim 12, wherein the ADT is selected from the group consisting of leuprolide, buserelin, gonadorelin, goserelin, histrelin, nafarelin, triptorelin, deslorelin, fertirelin, abarelix, cetrorelix, degarelix, ganirelix, ozarelix, elagolix, relugolix and linzagolix, or a pharmaceutically acceptable salt thereof.

15. The use of any one of claims 1 to 14, wherein the cancer is androgen dependent or androgen receptor (AR)-positive.

16. A combination for use in the treatment of cancer comprising:

(a) a compound of Formula (I):



(I),

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is H, F or Cl;

R^2 is C_1-C_4 alkyl, where said C_1-C_4 alkyl is optionally substituted by R^5;

R^3 is H or C_1-C_4 alkyl, where said C_1-C_4 alkyl is optionally substituted by R^6;

R^4 is H or F; and

each R^5 and R^6 is independently OH, F or C_1-C_2 alkoxy; and

(b) an antiandrogen.

17. The use of claim 16, wherein the compound of Formula (I) is 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1*H*-benz-imidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-*threo*-pentitol or a pharmaceutically acceptable salt thereof, and the antiandrogen is enzalutamide or a pharmaceutically acceptable salt or solvate thereof.

18. The use of claim 16 or 17, wherein the cancer is prostate cancer.

19. The use of claim 18, wherein the prostate cancer is mPC or nmPC.

20. The use of claim 18 or 19, wherein the prostate cancer is resistant to enzalutamide or abiraterone.